RZ Significantly Adds to Its Oregon Geothermal Resource

http://www.ariva.de/Raser_Significantly_Adds_to_Its_Oregon_Geothermal_Resource_Holdings_with_37_000_Acres_n2881776

Raser Significantly Adds to Its Oregon Geothermal Resource Holdings with 37,000 Acres

15:30 03.02.09

PROVO, Utah--(BUSINESS WIRE)--

Raser Technologies, Inc. (NYSE: RZ) announced today that it has entered into a long-term lease agreement with private land owners covering 37,000 acres of geothermal resources in Southeastern Oregon. The terms of the lease agreement were not specified, but include surface and other rights necessary to build geothermal power plants. The property includes a number of hot springs and wells that indicate the presence of significant geothermal resources. Working with the University of Utahs Energy and Geoscience Institute, Raser has determined this area is one of the more significantly promising geothermal systems, stated Brent M. Cook, CEO of Raser. We believe this is a vast resource area of mid temperature binary potential.

Well logs of drilling in the area over the last few decades in combination with our work done during the past 13 months in this area reveals heat and flows of geothermal fluids indicating that this is potentially a significant resource for geothermal development, stated Richard Clayton, Rasers Executive Vice President. The land is ideally located in southern Oregon so that the power generated from the resource can be sold into either the Oregon or California renewable energy markets.

About Raser Technologies

Raser (NYSE: RZ) is an environmentally-focused technology licensing and development company operating in two business segments. Rasers Power Systems segment is seeking to develop clean, renewable geothermal electric power plants and bottom-cycling operations, incorporating licensed heat transfer technology and Rasers Symetron technology developed internally by its Transportation and Industrial Technology segment. Rasers Transportation and Industrial Technology segment focuses on extended-range plug-in-hybrid vehicle solutions and using Rasers award-winning Symetron technology to improve the torque density and efficiency of the electric motors and drive systems used in electric and hybrid-electric vehicle powertrains and industrial applications. Further information on Raser may be found at: www.rasertech.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, but not limited to, statements regarding: our beliefs about preliminary drilling results; our beliefs about the potential for geothermal power generation on our leased properties; our belief about our ability to exploit the available geothermal resources; our beliefs about the strength and enforceability of our agreements; our beliefs about our ability to successfully negotiate power purchase agreements; and our beliefs about the geothermal market generally. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the competitive environment and our ability to compete in the industry; our ability to adapt our technology for geothermal applications; our ability to secure necessary permits; the strength of our intellectual property; our ability to attract, train and retain key personnel; and such other risks as identified in our quarterly report on Form 10-Q for the quarter ended September 30, 2008, as filed with the Securities and Exchange Commission, and all subsequent filings.

All forward-looking statements in this press release are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

(c)2007 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.

...another good trading-session of RZ

PDGI (Short-Interest ??)

http://www.shortsqueeze.com/?symbol=pdgi&submit=Short+Quote%99

Pharmanet Development Group Inc. $ 4.70
PDGI +3.36
Short Interest (Shares Short) 2,650,000
Days To Cover (Short Interest Ratio) 5.1
Short Percent of Float 14.51 %
Short Interest - Prior 2,100,700
Short % Increase / Decrease 26.15 %


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=35292296

PDGI -

PDGI Agrees to be Acquired by JLL Partners

http://ih.advfn.com/p.php?pid=nmona&cb=1233668713&article=36081865&symbol=N^PDGI

PharmaNet Development Group Agrees to be Acquired by JLL Partners

JLL to Commence Tender Offer for All Shares of Common Stock

PRINCETON, N.J., Feb. 3 /PRNewswire-FirstCall/ -- PharmaNet Development Group, Inc. (the "Company" or "PharmaNet") (NASDAQ:PDGI), a leading provider of clinical development services, today announced that it has signed a definitive merger agreement ("Merger Agreement") with affiliates of JLL Partners, Inc. ("JLL"). Under the terms of the Merger Agreement, JLL will commence a tender offer to purchase all of the outstanding shares of PharmaNet at a price of $5.00 per share in cash, representing a significant premium to PharmaNet's average closing price for the past thirty days.

The transaction values the Company's common stock at approximately $100 million. The transaction will be financed by a $250 million equity commitment from JLL which includes the necessary funds to retire the $144 million principal amount of the Company's outstanding convertible notes. The transaction is subject to the valid tender of a majority of PharmaNet common stock, regulatory approvals and other customary conditions, but it is not subject to any financing conditions. The parties expect the tender offer to close by the end of the first quarter of 2009.

PharmaNet's Board of Directors has approved the definitive Merger Agreement and the transactions contemplated thereby and have resolved to recommend that PharmaNet stockholders tender their shares in connection with the tender offer contemplated by the definitive Merger Agreement.

"The Board of Directors and I are very pleased to have a partner in JLL that recognizes the substantial value we have built in the PharmaNet Development Group franchise," said Jeffrey P. McMullen, President and Chief Executive Officer, PharmaNet Development Group, Inc. "We believe this transaction provides meaningful value to our stockholders while providing the solution to address the outstanding convertible notes."

"PharmaNet Development Group is well-positioned as a leading provider of outsourced clinical development services with a global infrastructure and an excellent reputation," said Ramsey Frank, Managing Director of JLL. "We look forward to working with the management team to enhance the Company's growth prospects and expand its portfolio of services."

The Merger Agreement provides for JLL to acquire PharmaNet in a two-step transaction. The first step will consist of a cash tender offer for all outstanding shares of PharmaNet common stock at a price of $5.00 per share in cash. In the second step, the tender offer will be followed by a merger in which any untendered outstanding shares of PharmaNet common stock will be converted into the right to receive the same cash price per share paid in the tender offer.

UBS Investment Bank is acting as exclusive financial advisor to PharmaNet, and Morgan, Lewis & Bockius, LLP is acting as PharmaNet's legal counsel in the transaction. Latham & Watkins LLP is acting as legal counsel in the transaction to the PharmaNet Board of Directors.

Skadden, Arps, Slate, Meagher & Flom LLP is acting as JLL's legal counsel in the transaction.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,500 employees and 41 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at http://www.pharmanet.com/.

About JLL Partners

JLL Partners is a New York-based leading private equity investment firm with $4.0 billion of capital under management. JLL's investment philosophy is to partner with outstanding management teams and invest with them in companies that can continue to grow. JLL has invested in a variety of industries with a special focus on healthcare services and financial services. More information can be found on their website, http://www.jllpartners.com/.

Important Information about the Tender Offer

This announcement and the description contained herein are for informational purposes only and are not an offer to purchase or a solicitation of an offer to sell securities of PharmaNet Development Group. The tender offer described herein has not yet been commenced. At the time the tender offer is commenced, JLL intends to file a tender offer statement on a Schedule TO containing an offer to purchase, a letter of transmittal and other related documents with the Securities and Exchange Commission. At the time the tender offer is commenced, PharmaNet Development Group, Inc. intends to file with the Securities and Exchange Commission a solicitation/recommendation statement on Schedule 14D-9 and, if required, will, file a proxy statement or information statement with the Securities and Exchange Commission in connection with the merger, the second step of the transaction, at a later date. Such documents will be mailed to stockholders of record and will also be made available for distribution to beneficial owners of common stock of PharmaNet Development Group, Inc. The solicitation of offers to buy common stock of PharmaNet Development Group will only be made pursuant to the offer to purchase, the letter of transmittal and related documents. Stockholders are advised to read the offer to purchase and the letter of transmittal, the solicitation/recommendation statement, the proxy statement, the information statement and all related documents, if and when such documents are filed and become available, as they will contain important information about the tender offer and proposed merger. Stockholders can obtain these documents when they are filed and become available free of charge from the Securities and Exchange Commission's website at http://www.sec.gov/, or from the information agent JLL selects. In addition, copies of the solicitation/recommendation statement, the proxy statement and other filings containing information about PharmaNet Development Group, Inc., the tender offer and the merger may be obtained, if and when available, without charge, by directing a request to PharmaNet Development Group, Inc. Attention: Anne-Marie Hess, Vice President, Investor Relations, at 504 Carnegie Center, Princeton, New Jersey 08540, or on PharmaNet Development Group's corporate website at http://www.pharmanet.com/.

Forward-Looking Statements

Certain statements made in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") and are subject to a variety of risks and uncertainties. Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Such forward-looking statements include PharmaNet Development Group, Inc.'s decision to enter into an agreement to be acquired by JLL, the ability of PharmaNet Development Group, Inc. and JLL to complete the transaction contemplated by the definitive agreement, including the parties' ability to satisfy the conditions set forth in the merger agreement, and the possibility of any termination of the definitive agreement. The forward-looking statements contained in this press release are based on our current expectations, and those made at other times will be based on our expectations when the statements are made. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, the expected timetable for completing the proposed transaction, the risk and uncertainty in connection with a strategic alternative process, not having sufficient funds to pay the principal due upon conversion of the outstanding notes or to repurchase our outstanding notes, which we may be required to do beginning in August 2009, the impact of the current economic environment, the impact of our indebtedness on our financial condition or results of operations and the terms of our outstanding indebtedness limiting our activities, the impact of the investigation by the Securities and Exchange Commission, our limited insurance coverage in connection with the settled securities class action lawsuit, limited additional coverage for the recently settled derivative actions and associated future legal fees, the potential liability related to the recently filed securities class action lawsuit, the impact of ongoing tax audits, our ability to generate new client contracts and maintain our existing clients' contracts, our evaluation of our backlog and the potential cancellation of contracts, the possibility we under-price our contracts or overrun cost estimates and the effect on our financial results by failure to receive approval for change orders and by delays in documenting change orders, our ability to implement our business strategy, international economic, political and other risks that could negatively affect our results of operations or financial position, changes in outsourcing trends and regulatory requirements affecting the branded pharmaceutical, biotechnology, generic drug and medical device industries, the reduction of expenditures by branded pharmaceutical, biotechnology, generic drug or medical device companies, actions or inspections by regulatory authorities and the impact on our clients' decisions to not award future contracts to us or to cancel existing contracts, the impact of healthcare reform, the fact that one or a limited number of clients may account for a large percentage of our revenues, the incurrence of significant taxes to repatriate funds, the fluctuation of our operating results from period to period, our assessment of our goodwill valuation, the impact of foreign currency fluctuations, tax law changes in Canada or in other foreign jurisdictions, investigations by governmental authorities regarding our inter-company transfer pricing policies or changes to their laws in a manner that could increase our effective tax rate or otherwise harm our business, our lack of the resources needed to compete effectively with larger competitors, our ability to continue to develop new assay methods for our analytical applications, or if our current assay methods are incorrect, our ability to compete with other entities offering bioanalytical laboratory services, our potential liability when conducting clinical trials, our handling and disposal of medical wastes, failure to comply with applicable governmental regulations, the loss of services of our key personnel and our ability to attract qualified staff, the continued effectiveness and availability of our information technology infrastructure, losses related to our self-insurance of our employees' healthcare costs in the United States, our ability to attract suitable investigators and volunteers for our clinical trials, the material weaknesses relating to our internal controls, and risks and uncertainties associated with discontinued operations.

Further information can be found in the Company's risk factors contained in its Annual Report on Form 10-K for the year ended December 31, 2007 and most recent filings. The Company does not undertake to update the disclosures made herein, and you are urged to read our filings with the Securities and Exchange Commission.

Contacts PharmaNet: Anne-Marie Hess JLL Partners: Peter Strothman Phone: (609) 951-6842 Phone: (212) 210-9347 E-mail: E-mail:

DATASOURCE: PharmaNet Development Group, Inc.

CONTACT: Anne-Marie Hess of PharmaNet, +1-609-951-6842,

; or Peter Strothman of JLL Partners, +1-212-210-9347,

Web Site: http://www.pharmanet.com/

PDGI Agrees to be Acquired by JLL Partners

http://ih.advfn.com/p.php?pid=nmona&cb=1233668713&article=36081865&symbol=N^PDGI

PharmaNet Development Group Agrees to be Acquired by JLL Partners

JLL to Commence Tender Offer for All Shares of Common Stock

PRINCETON, N.J., Feb. 3 /PRNewswire-FirstCall/ -- PharmaNet Development Group, Inc. (the "Company" or "PharmaNet") (NASDAQ:PDGI), a leading provider of clinical development services, today announced that it has signed a definitive merger agreement ("Merger Agreement") with affiliates of JLL Partners, Inc. ("JLL"). Under the terms of the Merger Agreement, JLL will commence a tender offer to purchase all of the outstanding shares of PharmaNet at a price of $5.00 per share in cash, representing a significant premium to PharmaNet's average closing price for the past thirty days.

The transaction values the Company's common stock at approximately $100 million. The transaction will be financed by a $250 million equity commitment from JLL which includes the necessary funds to retire the $144 million principal amount of the Company's outstanding convertible notes. The transaction is subject to the valid tender of a majority of PharmaNet common stock, regulatory approvals and other customary conditions, but it is not subject to any financing conditions. The parties expect the tender offer to close by the end of the first quarter of 2009.

PharmaNet's Board of Directors has approved the definitive Merger Agreement and the transactions contemplated thereby and have resolved to recommend that PharmaNet stockholders tender their shares in connection with the tender offer contemplated by the definitive Merger Agreement.

"The Board of Directors and I are very pleased to have a partner in JLL that recognizes the substantial value we have built in the PharmaNet Development Group franchise," said Jeffrey P. McMullen, President and Chief Executive Officer, PharmaNet Development Group, Inc. "We believe this transaction provides meaningful value to our stockholders while providing the solution to address the outstanding convertible notes."

"PharmaNet Development Group is well-positioned as a leading provider of outsourced clinical development services with a global infrastructure and an excellent reputation," said Ramsey Frank, Managing Director of JLL. "We look forward to working with the management team to enhance the Company's growth prospects and expand its portfolio of services."

The Merger Agreement provides for JLL to acquire PharmaNet in a two-step transaction. The first step will consist of a cash tender offer for all outstanding shares of PharmaNet common stock at a price of $5.00 per share in cash. In the second step, the tender offer will be followed by a merger in which any untendered outstanding shares of PharmaNet common stock will be converted into the right to receive the same cash price per share paid in the tender offer.

UBS Investment Bank is acting as exclusive financial advisor to PharmaNet, and Morgan, Lewis & Bockius, LLP is acting as PharmaNet's legal counsel in the transaction. Latham & Watkins LLP is acting as legal counsel in the transaction to the PharmaNet Board of Directors.

Skadden, Arps, Slate, Meagher & Flom LLP is acting as JLL's legal counsel in the transaction.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,500 employees and 41 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at http://www.pharmanet.com/.

About JLL Partners

JLL Partners is a New York-based leading private equity investment firm with $4.0 billion of capital under management. JLL's investment philosophy is to partner with outstanding management teams and invest with them in companies that can continue to grow. JLL has invested in a variety of industries with a special focus on healthcare services and financial services. More information can be found on their website, http://www.jllpartners.com/.

Important Information about the Tender Offer

This announcement and the description contained herein are for informational purposes only and are not an offer to purchase or a solicitation of an offer to sell securities of PharmaNet Development Group. The tender offer described herein has not yet been commenced. At the time the tender offer is commenced, JLL intends to file a tender offer statement on a Schedule TO containing an offer to purchase, a letter of transmittal and other related documents with the Securities and Exchange Commission. At the time the tender offer is commenced, PharmaNet Development Group, Inc. intends to file with the Securities and Exchange Commission a solicitation/recommendation statement on Schedule 14D-9 and, if required, will, file a proxy statement or information statement with the Securities and Exchange Commission in connection with the merger, the second step of the transaction, at a later date. Such documents will be mailed to stockholders of record and will also be made available for distribution to beneficial owners of common stock of PharmaNet Development Group, Inc. The solicitation of offers to buy common stock of PharmaNet Development Group will only be made pursuant to the offer to purchase, the letter of transmittal and related documents. Stockholders are advised to read the offer to purchase and the letter of transmittal, the solicitation/recommendation statement, the proxy statement, the information statement and all related documents, if and when such documents are filed and become available, as they will contain important information about the tender offer and proposed merger. Stockholders can obtain these documents when they are filed and become available free of charge from the Securities and Exchange Commission's website at http://www.sec.gov/, or from the information agent JLL selects. In addition, copies of the solicitation/recommendation statement, the proxy statement and other filings containing information about PharmaNet Development Group, Inc., the tender offer and the merger may be obtained, if and when available, without charge, by directing a request to PharmaNet Development Group, Inc. Attention: Anne-Marie Hess, Vice President, Investor Relations, at 504 Carnegie Center, Princeton, New Jersey 08540, or on PharmaNet Development Group's corporate website at http://www.pharmanet.com/.

Forward-Looking Statements

Certain statements made in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") and are subject to a variety of risks and uncertainties. Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Such forward-looking statements include PharmaNet Development Group, Inc.'s decision to enter into an agreement to be acquired by JLL, the ability of PharmaNet Development Group, Inc. and JLL to complete the transaction contemplated by the definitive agreement, including the parties' ability to satisfy the conditions set forth in the merger agreement, and the possibility of any termination of the definitive agreement. The forward-looking statements contained in this press release are based on our current expectations, and those made at other times will be based on our expectations when the statements are made. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, the expected timetable for completing the proposed transaction, the risk and uncertainty in connection with a strategic alternative process, not having sufficient funds to pay the principal due upon conversion of the outstanding notes or to repurchase our outstanding notes, which we may be required to do beginning in August 2009, the impact of the current economic environment, the impact of our indebtedness on our financial condition or results of operations and the terms of our outstanding indebtedness limiting our activities, the impact of the investigation by the Securities and Exchange Commission, our limited insurance coverage in connection with the settled securities class action lawsuit, limited additional coverage for the recently settled derivative actions and associated future legal fees, the potential liability related to the recently filed securities class action lawsuit, the impact of ongoing tax audits, our ability to generate new client contracts and maintain our existing clients' contracts, our evaluation of our backlog and the potential cancellation of contracts, the possibility we under-price our contracts or overrun cost estimates and the effect on our financial results by failure to receive approval for change orders and by delays in documenting change orders, our ability to implement our business strategy, international economic, political and other risks that could negatively affect our results of operations or financial position, changes in outsourcing trends and regulatory requirements affecting the branded pharmaceutical, biotechnology, generic drug and medical device industries, the reduction of expenditures by branded pharmaceutical, biotechnology, generic drug or medical device companies, actions or inspections by regulatory authorities and the impact on our clients' decisions to not award future contracts to us or to cancel existing contracts, the impact of healthcare reform, the fact that one or a limited number of clients may account for a large percentage of our revenues, the incurrence of significant taxes to repatriate funds, the fluctuation of our operating results from period to period, our assessment of our goodwill valuation, the impact of foreign currency fluctuations, tax law changes in Canada or in other foreign jurisdictions, investigations by governmental authorities regarding our inter-company transfer pricing policies or changes to their laws in a manner that could increase our effective tax rate or otherwise harm our business, our lack of the resources needed to compete effectively with larger competitors, our ability to continue to develop new assay methods for our analytical applications, or if our current assay methods are incorrect, our ability to compete with other entities offering bioanalytical laboratory services, our potential liability when conducting clinical trials, our handling and disposal of medical wastes, failure to comply with applicable governmental regulations, the loss of services of our key personnel and our ability to attract qualified staff, the continued effectiveness and availability of our information technology infrastructure, losses related to our self-insurance of our employees' healthcare costs in the United States, our ability to attract suitable investigators and volunteers for our clinical trials, the material weaknesses relating to our internal controls, and risks and uncertainties associated with discontinued operations.

Further information can be found in the Company's risk factors contained in its Annual Report on Form 10-K for the year ended December 31, 2007 and most recent filings. The Company does not undertake to update the disclosures made herein, and you are urged to read our filings with the Securities and Exchange Commission.

Contacts PharmaNet: Anne-Marie Hess JLL Partners: Peter Strothman Phone: (609) 951-6842 Phone: (212) 210-9347 E-mail: E-mail:

DATASOURCE: PharmaNet Development Group, Inc.

CONTACT: Anne-Marie Hess of PharmaNet, +1-609-951-6842,

; or Peter Strothman of JLL Partners, +1-212-210-9347,

Web Site: http://www.pharmanet.com/

PDGI Agrees to be Acquired by JLL Partners

http://ih.advfn.com/p.php?pid=nmona&cb=1233668713&article=36081865&symbol=N^PDGI

PharmaNet Development Group Agrees to be Acquired by JLL Partners

JLL to Commence Tender Offer for All Shares of Common Stock

PRINCETON, N.J., Feb. 3 /PRNewswire-FirstCall/ -- PharmaNet Development Group, Inc. (the "Company" or "PharmaNet") (NASDAQ:PDGI), a leading provider of clinical development services, today announced that it has signed a definitive merger agreement ("Merger Agreement") with affiliates of JLL Partners, Inc. ("JLL"). Under the terms of the Merger Agreement, JLL will commence a tender offer to purchase all of the outstanding shares of PharmaNet at a price of $5.00 per share in cash, representing a significant premium to PharmaNet's average closing price for the past thirty days.

The transaction values the Company's common stock at approximately $100 million. The transaction will be financed by a $250 million equity commitment from JLL which includes the necessary funds to retire the $144 million principal amount of the Company's outstanding convertible notes. The transaction is subject to the valid tender of a majority of PharmaNet common stock, regulatory approvals and other customary conditions, but it is not subject to any financing conditions. The parties expect the tender offer to close by the end of the first quarter of 2009.

PharmaNet's Board of Directors has approved the definitive Merger Agreement and the transactions contemplated thereby and have resolved to recommend that PharmaNet stockholders tender their shares in connection with the tender offer contemplated by the definitive Merger Agreement.

"The Board of Directors and I are very pleased to have a partner in JLL that recognizes the substantial value we have built in the PharmaNet Development Group franchise," said Jeffrey P. McMullen, President and Chief Executive Officer, PharmaNet Development Group, Inc. "We believe this transaction provides meaningful value to our stockholders while providing the solution to address the outstanding convertible notes."

"PharmaNet Development Group is well-positioned as a leading provider of outsourced clinical development services with a global infrastructure and an excellent reputation," said Ramsey Frank, Managing Director of JLL. "We look forward to working with the management team to enhance the Company's growth prospects and expand its portfolio of services."

The Merger Agreement provides for JLL to acquire PharmaNet in a two-step transaction. The first step will consist of a cash tender offer for all outstanding shares of PharmaNet common stock at a price of $5.00 per share in cash. In the second step, the tender offer will be followed by a merger in which any untendered outstanding shares of PharmaNet common stock will be converted into the right to receive the same cash price per share paid in the tender offer.

UBS Investment Bank is acting as exclusive financial advisor to PharmaNet, and Morgan, Lewis & Bockius, LLP is acting as PharmaNet's legal counsel in the transaction. Latham & Watkins LLP is acting as legal counsel in the transaction to the PharmaNet Board of Directors.

Skadden, Arps, Slate, Meagher & Flom LLP is acting as JLL's legal counsel in the transaction.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,500 employees and 41 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at http://www.pharmanet.com/.

About JLL Partners

JLL Partners is a New York-based leading private equity investment firm with $4.0 billion of capital under management. JLL's investment philosophy is to partner with outstanding management teams and invest with them in companies that can continue to grow. JLL has invested in a variety of industries with a special focus on healthcare services and financial services. More information can be found on their website, http://www.jllpartners.com/.

Important Information about the Tender Offer

This announcement and the description contained herein are for informational purposes only and are not an offer to purchase or a solicitation of an offer to sell securities of PharmaNet Development Group. The tender offer described herein has not yet been commenced. At the time the tender offer is commenced, JLL intends to file a tender offer statement on a Schedule TO containing an offer to purchase, a letter of transmittal and other related documents with the Securities and Exchange Commission. At the time the tender offer is commenced, PharmaNet Development Group, Inc. intends to file with the Securities and Exchange Commission a solicitation/recommendation statement on Schedule 14D-9 and, if required, will, file a proxy statement or information statement with the Securities and Exchange Commission in connection with the merger, the second step of the transaction, at a later date. Such documents will be mailed to stockholders of record and will also be made available for distribution to beneficial owners of common stock of PharmaNet Development Group, Inc. The solicitation of offers to buy common stock of PharmaNet Development Group will only be made pursuant to the offer to purchase, the letter of transmittal and related documents. Stockholders are advised to read the offer to purchase and the letter of transmittal, the solicitation/recommendation statement, the proxy statement, the information statement and all related documents, if and when such documents are filed and become available, as they will contain important information about the tender offer and proposed merger. Stockholders can obtain these documents when they are filed and become available free of charge from the Securities and Exchange Commission's website at http://www.sec.gov/, or from the information agent JLL selects. In addition, copies of the solicitation/recommendation statement, the proxy statement and other filings containing information about PharmaNet Development Group, Inc., the tender offer and the merger may be obtained, if and when available, without charge, by directing a request to PharmaNet Development Group, Inc. Attention: Anne-Marie Hess, Vice President, Investor Relations, at 504 Carnegie Center, Princeton, New Jersey 08540, or on PharmaNet Development Group's corporate website at http://www.pharmanet.com/.

Forward-Looking Statements

Certain statements made in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") and are subject to a variety of risks and uncertainties. Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Such forward-looking statements include PharmaNet Development Group, Inc.'s decision to enter into an agreement to be acquired by JLL, the ability of PharmaNet Development Group, Inc. and JLL to complete the transaction contemplated by the definitive agreement, including the parties' ability to satisfy the conditions set forth in the merger agreement, and the possibility of any termination of the definitive agreement. The forward-looking statements contained in this press release are based on our current expectations, and those made at other times will be based on our expectations when the statements are made. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, the expected timetable for completing the proposed transaction, the risk and uncertainty in connection with a strategic alternative process, not having sufficient funds to pay the principal due upon conversion of the outstanding notes or to repurchase our outstanding notes, which we may be required to do beginning in August 2009, the impact of the current economic environment, the impact of our indebtedness on our financial condition or results of operations and the terms of our outstanding indebtedness limiting our activities, the impact of the investigation by the Securities and Exchange Commission, our limited insurance coverage in connection with the settled securities class action lawsuit, limited additional coverage for the recently settled derivative actions and associated future legal fees, the potential liability related to the recently filed securities class action lawsuit, the impact of ongoing tax audits, our ability to generate new client contracts and maintain our existing clients' contracts, our evaluation of our backlog and the potential cancellation of contracts, the possibility we under-price our contracts or overrun cost estimates and the effect on our financial results by failure to receive approval for change orders and by delays in documenting change orders, our ability to implement our business strategy, international economic, political and other risks that could negatively affect our results of operations or financial position, changes in outsourcing trends and regulatory requirements affecting the branded pharmaceutical, biotechnology, generic drug and medical device industries, the reduction of expenditures by branded pharmaceutical, biotechnology, generic drug or medical device companies, actions or inspections by regulatory authorities and the impact on our clients' decisions to not award future contracts to us or to cancel existing contracts, the impact of healthcare reform, the fact that one or a limited number of clients may account for a large percentage of our revenues, the incurrence of significant taxes to repatriate funds, the fluctuation of our operating results from period to period, our assessment of our goodwill valuation, the impact of foreign currency fluctuations, tax law changes in Canada or in other foreign jurisdictions, investigations by governmental authorities regarding our inter-company transfer pricing policies or changes to their laws in a manner that could increase our effective tax rate or otherwise harm our business, our lack of the resources needed to compete effectively with larger competitors, our ability to continue to develop new assay methods for our analytical applications, or if our current assay methods are incorrect, our ability to compete with other entities offering bioanalytical laboratory services, our potential liability when conducting clinical trials, our handling and disposal of medical wastes, failure to comply with applicable governmental regulations, the loss of services of our key personnel and our ability to attract qualified staff, the continued effectiveness and availability of our information technology infrastructure, losses related to our self-insurance of our employees' healthcare costs in the United States, our ability to attract suitable investigators and volunteers for our clinical trials, the material weaknesses relating to our internal controls, and risks and uncertainties associated with discontinued operations.

Further information can be found in the Company's risk factors contained in its Annual Report on Form 10-K for the year ended December 31, 2007 and most recent filings. The Company does not undertake to update the disclosures made herein, and you are urged to read our filings with the Securities and Exchange Commission.

Contacts PharmaNet: Anne-Marie Hess JLL Partners: Peter Strothman Phone: (609) 951-6842 Phone: (212) 210-9347 E-mail: E-mail:

DATASOURCE: PharmaNet Development Group, Inc.

CONTACT: Anne-Marie Hess of PharmaNet, +1-609-951-6842,

; or Peter Strothman of JLL Partners, +1-212-210-9347,

Web Site: http://www.pharmanet.com/

Cell Therapeutics Is Down but Not Out

http://seekingalpha.com/article/118129-cell-therapeutics-is-down-but-not-out?source=feed

February 03, 2009
Mike Havrilla


Cell Therapeutics (CTIC) is a micro-cap cancer biotech which is down substantially in the past year in terms of stock price and market value, but not out after recently establishing a joint venture with Spectrum Pharma (SPPI) to market Zevalin, the potential for two FDA approvals this year (one new product, one label expansion), the potential for EMEA approval of Opaxio in the E.U., and a goal to become cash flow break-even by year-end.

A World Health Organization report released late last year estimates that cancer will overtake heart disease as the top cause of death in the world by 2010, which is part of an overall trend that predicts global cancer cases and deaths will more than double by 2030. The report predicts 27 million new cases of cancer will occur in 2030, which is a sharp increase from the 12 million cases of cancer in 2007.

Near-term events for CTIC include a special meeting for shareholders scheduled for 2/6/09 to obtain approval to increase the number of authorized shares of common stock (from 400M to 800M), conduct a reverse split (between 1:2-1:20), and increase the number of shares authorized for equity incentive and employee stock purchase plans – with the first two proposals aimed at regaining compliance for continued listing on the Nasdaq Capital Market by a deadline of 2/12/09.

CTIC will also be presenting at the 11th Annual BIO CEO & Investor Conference on Tuesday, February 10th at 9:30 AM in the Jade Room of the Waldorf-Astoria Hotel in New York City – click here for a link to the webcast for this event.

CTIC and SPPI have an upcoming PDUFA decision date (one of 14 extreme FDA trades, including companies with market caps below $100M with pending regulatory decisions) of 4/2/09 with a priority review designation for their sBLA to expand the label of Zevalin (Ibritumomab Tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma (NHL). Zevalin is currently approved for the treatment of relapsed or refractory low-grade or follicular B-cell NHL, which is now being marketed by the 50/50 joint venture between CTIC and SPPI called RIT Oncology.

CTIC received $15M in cash along with a 50% interest as part of the agreement with SPPI to form the joint venture to further develop and market Zevalin. CTIC is also eligible to receive an additional $15M in milestone payments based on achieving sales targets for the drug while doubling the size of the sales and marketing team behind the drug. There is also an option for CTIC to sell its 50% interest in RIT Oncology to SPPI for $18M at any time from 1/15/09 to 7/15/09, which is an important feature of the deal since CTIC has indicated that it will require additional financing during 2009 and the low stock price precludes equity-based financings.

In late January, CTIC announced that its plans to begin submission of a rolling NDA for pixantrone (BBR-2778) during 1Q09 for the treatment of relapsed, aggressive NHL – with FDA approval possible before year-end if a priority review is granted by the agency. There is a high likelihood of a priority review for this indication since it represents an unmet medical need with no currently approved drugs on the market. Last November, CTIC reported Phase 3 clinical trial results for pixantrone, which achieved its primary and secondary efficacy endpoints under a Special Protocol Assessment (SPA) approval by the FDA for the study.

Patients randomized to receive pixantrone in the study achieved an 11% (8 of 70) rate of confirmed complete remissions, as compared to no patients (out of 70) who were randomized to receive standard chemotherapy. Pixantrone also achieved a higher overall response rate of 37.1% (26 of 70) compared to patients received standard chemo at 14.3% (10 of 70). Patients receiving pixantrone also demonstrated a statistically significant improvement in progression-free survival compared to standard chemo (4.7 months versus 2.6 months). The FDA approval and launch of pixantrone could result in upfront + milestone payments from Novartis (NVS) if NVS chooses to exercise its exclusive, worldwide license to commercialize pixantrone.

Pixantrone is less damaging to the heart compared to the widely used and effective class of chemo drugs called anthracyclines and has demonstrated synergistic activity when combined with Rituxan and other treatments. Pixantrone also offers advantages in the way it is delivered (via regular IV infusion), compared to other agents which require pre-medication and central lines to administer.

Opaxio (paclitaxel poliglumex, CT-2103, formerly Xyotax) has a pending marketing authorization application (MAA) to the European Medicines Agency (EMEA) which was filed in March 2008 for the first-line treatment of patients with non-small cell lung cancer (NSCLC) (with performance status 2) as part of an exclusive licensing deal with NVS. Opaxio is designed to reduce the side effects of paclitaxel by linking it to a biodegradable polymer to create a new chemical entity which results in targeted delivery to solid tumors such as breast, ovarian, and lung cancers.

Clinical studies suggest that the metabolism of Opaxio by lung cancer cells may be influenced by estrogen, resulting in higher levels of the drug in women with lung cancer and the potential for increased efficacy. The MAA was filed based on non-inferiority or equivalent effectiveness and an improved safety profile for the treatment of NSCLC while the U.S. regulatory strategy will seek approval for maintenance treatment of ovarian cancer following complete remission after first-line treatment.

Brostallicin is currently in Phase 2 clinical development as a new type of synthetic cancer drug (a DNA minor groove binding agent) which has the potential to be a highly selective cancer treatment which is synergistic with standard chemo drugs and newer targeted therapies. CTIC owns the exclusive, worldwide rights to brostallicin and has completed six clinical trials for the drug, with results for three of the trials still pending.

While shares of CTIC have declined sharply in the past year, 2009 holds the promise for better days with the potential for three regulatory approvals (Zevalin sBLA, Pixantrone NDA, and Opaxio MAA), the potential for increased Zevalin sales from the RTI Oncology joint venture, the option to sell its stake in the joint venture to SPPI for $18M through mid-July, and the goal of becoming cash flow break-even by year-end.

Raser Signs US $15M Line of Credit Agreement

http://www.renewableenergyworld.com/rea/news/story?id=54642&src=rss

2. Februar 2009
Raser Signs US $15M Line of Credit Agreement
Utah, United States [RenewableEnergyWorld.com]

Raser Technologies Inc. announced the signing of a line of credit agreement, pursuant to which Raser may borrow up to US $15 million. Raser signed the credit agreement with a syndicate of four lenders, including an entity controlled by the company's chairman, Kraig Higginson. The company obtained the line of credit in order to provide working capital for general corporate purposes.

Under the agreement, advances to Raser are subject to the final approval of the lenders and accrue interest at the rate of 10% per year. Unless the lenders agree to a later date, the line of credit will mature and amounts borrowed must be repaid by November 15, 2009.

Under the agreement, each lender will also receive warrants to purchase Raser’s common stock for each advance of funds made under the line of credit. The number of warrants will be equal to 50% of the total amounts funded by the lender divided by the price of our common stock at the time of the advance. The warrants will have an exercise price of US $6.00 per share of common stock.

“This credit agreement helps to prudently fund our growth and development during these challenging economic times,” said Martin Petersen, Raser’s CFO. “We will continue to explore other non-equity based financial structures to provide the capital to complete our 2009 projects and initiate the development of additional future projects. Our ability to continue to access capital in this economy underscores the importance of renewable energy projects and our ability to complete geothermal projects quickly.”


"We will continue to explore other non-equity based financial structures to provide the capital to complete our 2009 projects and initiate the development of additional future projects."

-- Martin Petersen, CFO, Raser

RZ -



Short Quote: http://www.shortsqueeze.com/?symbol=rz&submit=Short+Quote%99

RZ -




Short Quote: http://www.shortsqueeze.com/?symbol=rz&submit=Short+Quote%99

RZ

CTIC

KV/A

Share Structure ( AS / OS )

...wrote yesterday an email to mr. Knopick - following the answer...

Authorized is $950M
Can't provide outstanding until auditors check.

All the Best,

Matthew L. Schissler
Chairman & CEO

-----Original Message-----
From: Ax xxx [mailto:xxx@xxx.de]
Sent: Friday, January 30, 2009 12:28 AM
To: pknopick@eandecommunications.com
Subject: CORD BLOOD AMERICA (CBAI) - currently AS / OS ??

Dear Mr. Knopick

can you communicate momentary number AS and OS of CBAI to me?

Regards
Ax xxx

RZ up 8%


30.01.2009 15:08
Raser Signs $15 Million Line of Credit Agreement

http://www.finanznachrichten.de/nachrichten-2009-01/12982139-raser-signs-dollar-15-million-line-of-credit-agreement-004.htm

Raser Technologies, Inc. (News) (NYSE: RZ) announced today the signing of a line of credit agreement, pursuant to which Raser may borrow up to $15 million. Raser signed the credit agreement with a syndicate of four lenders, including an entity controlled by the Company’s Chairman, Kraig Higginson. The Company obtained the line of credit in order to provide working capital for general corporate purposes. The Company expects that borrowings under the line of credit will be repaid primarily with proceeds from other financing arrangements the Company intends to close in connection with the development of its geothermal power projects.

Under the agreement, advances to Raser are subject to the final approval of the lenders and accrue interest at the rate of 10% per annum. Unless the lenders agree to a later date, the line of credit will mature and amounts borrowed must be repaid by November 15, 2009 or earlier if certain financing arrangements for the development of Raser’s geothermal power projects are completed and put in place. Under the agreement, each lender will also receive warrants to purchase Raser’s common stock for each advance of funds made under the line of credit. The number of warrants will be equal to 50% of the total amounts funded by the lender divided by the price of our common stock at the time of the advance. The warrants will have an exercise price of $6.00 per share of common stock.

”This credit agreement helps to prudently fund our growth and development during these challenging economic times,” said Martin Petersen, Raser’s Chief Financial Officer. ”We will continue to explore other non-equity based financial structures to provide the capital to complete our 2009 projects and initiate the development of additional future projects. Our ability to continue to access capital in this economy underscores the importance of renewable energy projects and our ability to complete geothermal projects quickly.”

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities. The securities to be issued to the lenders and the shares of Raser common stock issuable upon exercise of the securities have not been registered under the Securities Act of 1933 or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Raser Technologies

Raser (NYSE: RZ) is an environmentally focused technology licensing and development company operating in two business segments. Raser’s Power Systems segment is seeking to develop clean, renewable geothermal electric power plants and bottom-cycling operations, incorporating licensed heat transfer technology and Raser’s Symetron™ technology developed internally by its Transportation and Industrial Technology segment. Raser’s Transportation and Industrial Technology segment focuses on extended-range plug-in-hybrid vehicle solutions and using Raser’s Symetron™ technology to improve the torque density and efficiency of the electric motors and drive systems used in electric and hybrid-electric vehicle powertrains and industrial applications.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, but not limited to, statements regarding: our beliefs about the potential for geothermal power generation on our leased properties and its qualification for certain federal tax credits; our beliefs about our ability to exploit the available geothermal resources; our beliefs about the ability of the lenders to provide cash under the terms of the line of credit agreement; our beliefs about our ability to obtain adequate development and permanent project funding or other financing arrangements for our geothermal power projects; our beliefs about our ability to utilize our technology and other available technologies to produce electric power from the available resources; and our beliefs about the geothermal market in general. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the competitive environment and our ability to compete in the industry; our ability to adapt our technology and third-party technology for the intended applications; our ability to secure necessary permits; the strength of our intellectual property; our ability to attract, train and retain key personnel; and such other risks as identified in our quarterly report on Form 10-Q for the quarter ended September 30, 2008, as filed with the Securities and Exchange Commission, and all subsequent filings.

All forward-looking statements in this press release are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Contacts:

Raser Technologies, Inc.
Richard Putnam, Investor Relations, 801-765-1200
investorrelations@rasertech.com
or
Hayden Communications, Inc
Cameron Donahue, 651-653-1854
cameron@haydenir.com

****************************************************************
Short Quote: http://www.shortsqueeze.com/?symbol=rz&submit=Short+Quote%99

RZ - Raser Signs $15 Million Line of Credit Agreement

30.01.2009 15:08
Raser Signs $15 Million Line of Credit Agreement

http://www.finanznachrichten.de/nachrichten-2009-01/12982139-raser-signs-dollar-15-million-line-of-credit-agreement-004.htm

Raser Technologies, Inc. (News) (NYSE: RZ) announced today the signing of a line of credit agreement, pursuant to which Raser may borrow up to $15 million. Raser signed the credit agreement with a syndicate of four lenders, including an entity controlled by the Company’s Chairman, Kraig Higginson. The Company obtained the line of credit in order to provide working capital for general corporate purposes. The Company expects that borrowings under the line of credit will be repaid primarily with proceeds from other financing arrangements the Company intends to close in connection with the development of its geothermal power projects.

Under the agreement, advances to Raser are subject to the final approval of the lenders and accrue interest at the rate of 10% per annum. Unless the lenders agree to a later date, the line of credit will mature and amounts borrowed must be repaid by November 15, 2009 or earlier if certain financing arrangements for the development of Raser’s geothermal power projects are completed and put in place. Under the agreement, each lender will also receive warrants to purchase Raser’s common stock for each advance of funds made under the line of credit. The number of warrants will be equal to 50% of the total amounts funded by the lender divided by the price of our common stock at the time of the advance. The warrants will have an exercise price of $6.00 per share of common stock.

”This credit agreement helps to prudently fund our growth and development during these challenging economic times,” said Martin Petersen, Raser’s Chief Financial Officer. ”We will continue to explore other non-equity based financial structures to provide the capital to complete our 2009 projects and initiate the development of additional future projects. Our ability to continue to access capital in this economy underscores the importance of renewable energy projects and our ability to complete geothermal projects quickly.”

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities. The securities to be issued to the lenders and the shares of Raser common stock issuable upon exercise of the securities have not been registered under the Securities Act of 1933 or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Raser Technologies

Raser (NYSE: RZ) is an environmentally focused technology licensing and development company operating in two business segments. Raser’s Power Systems segment is seeking to develop clean, renewable geothermal electric power plants and bottom-cycling operations, incorporating licensed heat transfer technology and Raser’s Symetron™ technology developed internally by its Transportation and Industrial Technology segment. Raser’s Transportation and Industrial Technology segment focuses on extended-range plug-in-hybrid vehicle solutions and using Raser’s Symetron™ technology to improve the torque density and efficiency of the electric motors and drive systems used in electric and hybrid-electric vehicle powertrains and industrial applications.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, but not limited to, statements regarding: our beliefs about the potential for geothermal power generation on our leased properties and its qualification for certain federal tax credits; our beliefs about our ability to exploit the available geothermal resources; our beliefs about the ability of the lenders to provide cash under the terms of the line of credit agreement; our beliefs about our ability to obtain adequate development and permanent project funding or other financing arrangements for our geothermal power projects; our beliefs about our ability to utilize our technology and other available technologies to produce electric power from the available resources; and our beliefs about the geothermal market in general. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the competitive environment and our ability to compete in the industry; our ability to adapt our technology and third-party technology for the intended applications; our ability to secure necessary permits; the strength of our intellectual property; our ability to attract, train and retain key personnel; and such other risks as identified in our quarterly report on Form 10-Q for the quarter ended September 30, 2008, as filed with the Securities and Exchange Commission, and all subsequent filings.

All forward-looking statements in this press release are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Contacts:

Raser Technologies, Inc.
Richard Putnam, Investor Relations, 801-765-1200
investorrelations@rasertech.com
or
Hayden Communications, Inc
Cameron Donahue, 651-653-1854
cameron@haydenir.com

...acquired some shares over Berlin

http://www.ariva.de/quote/simple.m?secu=910077

GNPH Enters Into Agreement to Purchase Hongrui Pharmaceuticals

http://www.finanznachrichten.de/nachrichten-2009-01/12973354-genesis-pharmaceuticals-enters-into-agreement-to-purchase-hongrui-pharmaceuticals-and-acquire-22-new-traditional-chinese-medicines-008.htm
29.01.2009 20:38
Genesis Pharmaceuticals Enters Into Agreement to Purchase Hongrui Pharmaceuticals, and Acquire 22 New Traditional Chinese Medicines

LAIYANG, China, Jan. 29 /PRNewswire-Asia-FirstCall/ -- Genesis Pharmaceuticals Enterprises, (News) Inc. (BULLETIN BOARD: GNPH) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that Laiyang Jiangbo Pharmaceutical Co., Ltd. ("Laiyang"), a wholly-owned subsidiary of the Company, entered into an Assets Transfer Contract (the "Contract") with Shandong Chinese Traditional Medicine College (the "Medicine College") and Hongrui Pharmaceuticals, Ltd. ("Hongrui"), a wholly-owned subsidiary of the Medicine College, pursuant to which Laiyang will purchase the majority of the assets owned by Hongrui, including all tangible assets, including without limitation, all manufacturing and office buildings, land, equipment and inventories and all rights to manufacture and distribute Hongrui's 22 Traditional Chinese Medicines ("TCM"), for a total purchase price of RMB110 million (approximately $16.1 million) consisting of RMB66 million in cash (approximately US$9.6 million) and 643,651 shares of the Company's common stock. Because the current fair market value share price is approximately US$2.6 million; the Company has valued the transaction at approximately US$12.2 million.

The purchase will be consummated in stages following the receipt by the parties of all required regulatory approvals including the approval of the Shandong Province Food and Drug Administration ("SFDA") and the approval of the Shandong State Owned Assets Administration Department. As of January 23, 2009, this transaction has been approved by the Shandong State Owned Assets Administration Department and certain assets were transferred to Laiyang. Pursuant to the terms of the Contract, the purchase consideration will be paid to the Medicine College as follows: RMB20 million (approximately US$2.9 million) of the purchase price will be paid to the Medicine College in cash within one month of the initial transfer of assets to Laiyang (by February 23, 2009). Another RMB46 million (approximately US$6.7 million) of the purchase price will be paid to the Medicine College in cash once the SFDA transfers the owner registration of Hongrui's 22 TCM products from Hongrui to Laiyang. The Contract provides that in the event that the SFDA does not approve the transfer of the ownership of Hongrui's 22 TCM products from Hongrui to Laiyang that Laiyang may cancel the Contract and rescind any transfers and payments previously consummated or made. The remaining RMB44 million of the purchase price will be paid to the Medicine College in the form of 643,651 newly issued shares of Genesis common stock within one year of the date of the execution of the Contract.

Hongrui Pharmaceuticals, Limited

Hongrui was founded in 1971 as an affiliate business of the Medicine College. It has a 33,350 square meter production and distribution facility located in the eastern part of Laiyang city which includes a 5,330 square meter plant and a 1,880 square meter warehouse. Hongrui has approximately 120 employees. Hongrui's revenue for 2007 was RMB113 million. Hongrui's revenue for the eight months ended August 31, 2008, was RMB 80.6 million, with an over 10% net profit margin. Laiyang will acquire Hongrui's production and distribution facility, equipment and inventories.

Hongrui produces a number of traditional Chinese medicines in tablet, capsule, syrup, pill and cream form which are widely used to cure gynecologic diseases, fevers, colds and coughs, pediatric diseases, and for daily health care. Hongrui also developed a drug used to treat bone and bone marrow inflammations for which it owns the intellectual property rights and is the exclusive manufacturer in China.

Hongrui groups its drugs into series:

-- Gynecology series - Motherwort Herb electuary, Motherwort Herb granules and Yimu granules to help ease labor pains

-- Laiyang Pear series - Laiyang Pear syrup and pulps to control coughs arising from various factors

-- Cold series - Syrup and granules, and Radix Isatidis granules, to help reduce fevers and control coughs

-- Pediatric series - Oral liquids to control children's coughs, asthma and fever

-- Traditional Cure series - Liuweidihuang pills to help improve memory, Aplotaxis Carminative pills for upset stomachs, and pills for a variety of liver and stomach ailments

Acquisition by Genesis

The acquisition of Hongrui by Laiyang will increase Genesis' product portfolio from 6 to 28 products during a time when the Chinese SFDA is tightening its standards and slowing down its approval process for new drugs. A larger number of TCM products will help increase the Company's presence in the OTC drug market and help balance Genesis' OTC sales with its sales of prescription drugs.

After the asset transfer is complete, Genesis will begin manufacturing, labeling and distributing the TCM products it purchased from Hongrui under its own brand name "Jiangbo." As a first phase, Genesis selected 11 Hongrui products to produce and distribute. These 11 TCM drugs have had the highest sales volumes and profit margins of all of Hongrui's products.

"After months of due diligence, we are pleased to enter into a purchase agreement with the Medicine College through which we will acquire Hongrui. Genesis is accelerating its growth by acquiring profitable products from Hongrui which we will manufacture and then distribute through our sales network. We estimate that this acquisition will increase Genesis' revenues by approximately RMB150 million, and net income by approximately RMB24 million, in the twelve months after closing," said Mr. Wubo Cao, CEO of Genesis. "We plan to integrate Hongrui's production and sales into our existing manufacturing and sales network. We believe that our product mix after this acquisition will enable us to better meet the demands of the growing OTC drug market in China."

About Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, and granule form.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the acquisition of Hongrui. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact: Genesis Pharmaceuticals CCG Investor Relations, Inc. Enterprises, Inc. Mr. Crocker Coulson, President Ms. Elsa Sung, CFO Phone: (646) 213-1915 Phone: (954) 727-8435 E-mail: crocker.coulson@ccgir.com E-mail: elsasung@jiangbo.com http://www.ccgirasia.com/ http://www.genesispharmaceuticals.com/

...too long without signs of life

- but I can wait, was a 'gift'

thanks! ...added some

need assistance. Opinions to CENX

short/longtime-invest...

pre-market $.16 ($.15 and rising)

Cell Therapeutics Inc. [CTIC]

...markets lymphoma drug, Zevalin, in the United States. Zevalin is an FDA-approved radioimmunotherapeutic for treating lymphoma. The company also develops, acquires, and commercializes novel treatments for cancer. In addition, Cell Therapeutics develops XYOTAX for the treatment of non-small cell lung cancer and ovarian cancer; Pixantrone, a novel compound in the class of drugs known as anthracyclines, for non-Hodgkin’s lymphoma; and Brostallicin, which is in first-line Phase II study for the treatment of sarcoma. The company has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd. and PG-TXL Company, L.P. It has a joint venture with Spectrum Pharmaceuticals, Inc. to commercialize and develop Zevalin(R) in the United States. The company was founded in 1991 and is headquartered in Seattle, Washington.

*****************************************************************
...added to my LONGTIME-portfolio some "CTIC"

HOMEPAGE: http://www.cticseattle.com/

IHUB-THREAD: http://ih.advfn.com/p.php?pid=squote&symbol=CTIC

STOCKCHARTS: http://stockcharts.com/h-sc/ui?s=ctic&p=D&b=5&g=0&id=0

INVESTORS: http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-IRHome

******************************************************************

01/27/09 Pixantrone Pre-NDA Communication from FDA
http://ih.advfn.com/p.php?pid=nmona&cb=1233142863&article=35972975&symbol=N%5ECTIC

..."With the potential for three drug approvals in 2009 we are on track to meet our objective of cash flow break even in the fourth quarter of this year."

01/28/09 Pixantrone Increases Progression-Free Survival by 81%
http://ih.advfn.com/p.php?pid=nmona&cb=1233142863&article=35990098&symbol=N%5ECTIC

..."We always believed the effectiveness of pixantrone would translate into a meaningful difference for patients with relapsed aggressive NHL...

CTIC - Pixantrone Increases Progression-Free Survival by 81%

http://ih.advfn.com/p.php?pid=nmona&cb=1233142206&article=35990098&symbol=N^CTIC

Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggress

SEATTLE, Jan. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today preliminary progression-free survival (PFS) results from its pivotal phase III EXTEND (PIX301) trial of pixantrone that show patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) treated with pixantrone experienced a statistically significant improvement in median progression-free survival, compared with other single-agent chemotherapeutic agents (4.7 months vs. 2.6 months, p < 0.01, pixantrone vs. standard chemotherapy) based on an intent to treat analysis. PFS was a prospectively defined secondary endpoint in the study.

"We always believed the effectiveness of pixantrone would translate into a meaningful difference for patients with relapsed aggressive NHL and these dramatic and significant differences in PFS in this tough to treat group of patients provides that evidence," stated James A. Bianco, M.D. Chief Executive Officer of CTI. "Pixantrone is the first agent in this patient population to demonstrate a significant and meaningful PFS advantage. We believe these data will support a priority review designation on our New Drug Application (NDA) once we share them with the Food and Drug Administration (FDA)."

The Company had previously announced that its pivotal phase III (PIX 301) EXTEND trial had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) and unconfirmed complete remissions (CRu) compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02) with no patients in the standard chemotherapy arm achieving a confirmed complete remission. Additionally, pixantrone treatment also significantly increased the overall response rate (CR/CRu+PR) (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003). PFS, CR/CRu and ORR were determined by an independent assessment panel that was blinded to the treatment assignments.

The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent Data Safety Monitoring Committee and no serious concerns were raised.

The EXTEND clinical trial is a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician. The trial was designed to examine the complete remission or unconfirmed complete remission rate, overall survival and progression-free survival. The study received Special Protocol Assessment approval from the FDA in 2004 and pixantrone has received fast track designation for this indication.

The Company announced on January 27, 2009 that after a pre-NDA communication with the FDA, it expects to begin submission of a rolling NDA and request priority review for pixantrone to treat relapsed aggressive NHL in the first quarter of 2009.

About Pixantrone

Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the results of complete safety information, the ability of the company to file a rolling NDA in the first quarter of 2009,a determination by the FDA that the PIX301 trial is insufficient to support an NDA filing and that the FDA would grant priority review, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the Company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 E: http://www.celltherapeutics.com/press_room

Investors Contact: Ed Bell T: 206.272.4345 Lindsey Jesch Logan T : 206.272.4347 F : 206.272.4434 E: http://www.celltherapeutics.com/investors

DATASOURCE: Cell Therapeutics, Inc.

CONTACT: Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,

, or Investors, Ed Bell, +1-206-272-4345, or Lindsey Jesch

Logan, +1-206-272-4347, fax, +1-206-272-4434,

Web site: http://www.celltherapeutics.com/

CTIC - Pixantrone Increases Progression-Free Survival by 81%

http://finance.yahoo.com/news/Pixantrone-Increases-prnews-14176737.html

Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial

* Wednesday January 28, 2009, 1:30 am EST

SEATTLE, Jan. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today preliminary progression-free survival (PFS) results from its pivotal phase III EXTEND (PIX301) trial of pixantrone that show patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) treated with pixantrone experienced a statistically significant improvement in median progression-free survival, compared with other single-agent chemotherapeutic agents (4.7 months vs. 2.6 months, p < 0.01, pixantrone vs. standard chemotherapy) based on an intent to treat analysis. PFS was a prospectively defined secondary endpoint in the study.

"We always believed the effectiveness of pixantrone would translate into a meaningful difference for patients with relapsed aggressive NHL and these dramatic and significant differences in PFS in this tough to treat group of patients provides that evidence," stated James A. Bianco, M.D. Chief Executive Officer of CTI. "Pixantrone is the first agent in this patient population to demonstrate a significant and meaningful PFS advantage. We believe these data will support a priority review designation on our New Drug Application (NDA) once we share them with the Food and Drug Administration (FDA)."

The Company had previously announced that its pivotal phase III (PIX 301) EXTEND trial had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) and unconfirmed complete remissions (CRu) compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02) with no patients in the standard chemotherapy arm achieving a confirmed complete remission. Additionally, pixantrone treatment also significantly increased the overall response rate (CR/CRu+PR) (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003). PFS, CR/CRu and ORR were determined by an independent assessment panel that was blinded to the treatment assignments.

The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent Data Safety Monitoring Committee and no serious concerns were raised.

The EXTEND clinical trial is a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician. The trial was designed to examine the complete remission or unconfirmed complete remission rate, overall survival and progression-free survival. The study received Special Protocol Assessment approval from the FDA in 2004 and pixantrone has received fast track designation for this indication.

The Company announced on January 27, 2009 that after a pre-NDA communication with the FDA, it expects to begin submission of a rolling NDA and request priority review for pixantrone to treat relapsed aggressive NHL in the first quarter of 2009.

About Pixantrone

Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the results of complete safety information, the ability of the company to file a rolling NDA in the first quarter of 2009,a determination by the FDA that the PIX301 trial is insufficient to support an NDA filing and that the FDA would grant priority review, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the Company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch Logan
T : 206.272.4347
F : 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors

Satyam shares rise for 8th day as bidders circle

...U.S.-based outsourcer iGate has said it would be interested in buying Satyam with PE help.

http://www.finanznachrichten.de/nachrichten-2009-01/12953927-satyam-shares-rise-for-8th-day-as-bidders-circle-020.htm

28.01.2009 11:02
Satyam shares rise for 8th day as bidders circle

NEW DELHI, Jan 28 (Reuters) - Shares in Satyam Computer Services (News) rallied as much as 18 percent on Wednesday, extending gains to an eighth session, after the fraud-hit outsourcer's new board said there had been wide bidding interest and a transparent process would be devised.

Boston Consulting Group, which was appointed on Tuesday as management adviser in the revival process, sees Satyam as a quality company with a viable business, one of its India directors told Reuters on Wednesday.

'You have to understand that the quality and capability of this company ... just because a few people did some fraud and created an issue on the balance sheet does not mean that this company is not a very high-quality company,' said James Abraham, a director and partner at BCG's Indian unit.

Satyam, India's No. 4 software exporter, was plunged into a crisis after its founder Ramalinga Raju resigned as chairman earlier this month, revealing profits had been falsified for years and $1 billion of cash on the books did not exist.

The government stepped in to limit the damage from India's biggest corporate fraud and appointed a new six-member board, which has been meeting on a weekly basis.

On Tuesday, it appointed Goldman Sachs and Avendus, an Indian investment bank, to identify strategic investors and obtain expressions of interest.

Engineering conglomerate Larsen&Toubro, which also runs a small software firm, has trebled its stake in Satyam to 12 percent and its chairman said on Tuesday it would not be averse to raise it further to 15 percent.

Under Indian law, this would trigger an open offer for a further 20 percent.

'The market is expecting some kind of an open offer,' said Gajendra Nagpal, CEO at Unicon Financial. 'And some confidence has been restored with hopes that shares are going to a credible hand like L&T.'

The open offer is usually based on the average price over the last six months or some 335 rupees, according to Thomson Reuters data, but Nagpal said there was a possibility the market regulator could relax rules as Satyam shares had plunged.

'We are hoping that it won't be less than 90 rupees. So it's a punter's call to make some quick money,' Nagpal said.

Satyam shares were trading 17.9 percent up at 55.60 rupees at 0839 GMT, after touching a high of 55.75 rupees, which was their highest since Jan. 7, the day Raju revealed the fraud and resigned.

T.N. Manoharan, a member of Satyam's new board, said on Tuesday it had received several proposals from companies as well as buyout firms and would devise 'appropriate, fair and transparent measures' for enbling open bids.

U.S.-based outsourcer iGate has said it would be interested in buying Satyam with PE help.

Satyam's board members have said they were arranging funds from banks and financial institutions, including state-run Life Insurance Corp that owns about 4.3 percent of Satyam.

The board said on Tuesday January salaries would be paid as scheduled from internal accruals and receivables. The proposed management structure would be released this week, the board said.

(Reporting by Devidutta Tripathy; Editing by Ranjit Gangadharan) Keywords: SATYAM/

(devidutta.tripathy@thomsonreuters.com; +91 11 4178 1009; Reuters Messaging: devidutta.tripathy.reuters.com@reuters.net)

COPYRIGHT

Copyright Thomson Reuters 2009. All rights reserved.

The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.

Satyam shares rise for 8th day as bidders circle

http://www.finanznachrichten.de/nachrichten-2009-01/12953927-satyam-shares-rise-for-8th-day-as-bidders-circle-020.htm

28.01.2009 11:02
Satyam shares rise for 8th day as bidders circle

NEW DELHI, Jan 28 (Reuters) - Shares in Satyam Computer Services (News) rallied as much as 18 percent on Wednesday, extending gains to an eighth session, after the fraud-hit outsourcer's new board said there had been wide bidding interest and a transparent process would be devised.

Boston Consulting Group, which was appointed on Tuesday as management adviser in the revival process, sees Satyam as a quality company with a viable business, one of its India directors told Reuters on Wednesday.

'You have to understand that the quality and capability of this company ... just because a few people did some fraud and created an issue on the balance sheet does not mean that this company is not a very high-quality company,' said James Abraham, a director and partner at BCG's Indian unit.

Satyam, India's No. 4 software exporter, was plunged into a crisis after its founder Ramalinga Raju resigned as chairman earlier this month, revealing profits had been falsified for years and $1 billion of cash on the books did not exist.

The government stepped in to limit the damage from India's biggest corporate fraud and appointed a new six-member board, which has been meeting on a weekly basis.

On Tuesday, it appointed Goldman Sachs and Avendus, an Indian investment bank, to identify strategic investors and obtain expressions of interest.

Engineering conglomerate Larsen&Toubro, which also runs a small software firm, has trebled its stake in Satyam to 12 percent and its chairman said on Tuesday it would not be averse to raise it further to 15 percent.

Under Indian law, this would trigger an open offer for a further 20 percent.

'The market is expecting some kind of an open offer,' said Gajendra Nagpal, CEO at Unicon Financial. 'And some confidence has been restored with hopes that shares are going to a credible hand like L&T.'

The open offer is usually based on the average price over the last six months or some 335 rupees, according to Thomson Reuters data, but Nagpal said there was a possibility the market regulator could relax rules as Satyam shares had plunged.

'We are hoping that it won't be less than 90 rupees. So it's a punter's call to make some quick money,' Nagpal said.

Satyam shares were trading 17.9 percent up at 55.60 rupees at 0839 GMT, after touching a high of 55.75 rupees, which was their highest since Jan. 7, the day Raju revealed the fraud and resigned.

T.N. Manoharan, a member of Satyam's new board, said on Tuesday it had received several proposals from companies as well as buyout firms and would devise 'appropriate, fair and transparent measures' for enbling open bids.

U.S.-based outsourcer iGate has said it would be interested in buying Satyam with PE help.

Satyam's board members have said they were arranging funds from banks and financial institutions, including state-run Life Insurance Corp that owns about 4.3 percent of Satyam.

The board said on Tuesday January salaries would be paid as scheduled from internal accruals and receivables. The proposed management structure would be released this week, the board said.

(Reporting by Devidutta Tripathy; Editing by Ranjit Gangadharan) Keywords: SATYAM/

(devidutta.tripathy@thomsonreuters.com; +91 11 4178 1009; Reuters Messaging: devidutta.tripathy.reuters.com@reuters.net)

COPYRIGHT

Copyright Thomson Reuters 2009. All rights reserved.

The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.

BarackStocks.com Announces Commentary Related to Wind Energy Companies

http://ih.advfn.com/p.php?pid=nmona&cb=1233071802&article=35978650&symbol=NB^NCEN

http://www.alphatrade.com/news/stories/AM/2009-01-27/GNW/200901270900PRIMZONEFULLFEED158393.html

CTIC on a run (after yesterday again!)

http://ih.advfn.com/p.php?pid=squote&symbol=CTIC

L&T shares weak on likely Satyam open offer

... in case of an open offer, the engineering and construction major would have to offer Satyam shareholders almost six times the software company's current market price.

http://economictimes.indiatimes.com/articleshow/4036409.cms

L&T shares weak on likely Satyam open offer
27 Jan 2009, 1423 hrs IST, ET Bureau

MUMBAI: Shares of Larsen & Toubro were weak in a strong market after the company indicated it would hike its stake in Satyam Computer beyond
15%, a move that will trigger an open offer.

L&T investors are concerned that, in case of an open offer, the engineering and construction major would have to offer Satyam shareholders almost six times the software company's current market price.

As per the existing norms, if an acquirer buys more than 15% in a listed entity, he has to mandatorily make an open offer to buy another 20% from smaller shareholders.

Though a section of the market is betting authorities may relax the open offer norms in L&T's case, given the enthusiasm shown by the government to end the matter, it is still not clear to what extent would the rules be relaxed.

At 1:28 pm, L&T shares were down 1.1% at Rs633.85. Satyam shares up 20% at Rs46.50.

Satyam jumps as L&T says may raise stake

...'Somebody is going to jump into the fray. Once what we know becomes more clear and once others come to know, the price will move,' he added.

http://www.finanznachrichten.de/nachrichten-2009-01/12940646-update-1-satyam-jumps-as-l-t-says-may-raise-stake-020.htm

27.01.2009 09:57
UPDATE 1-Satyam jumps as L&T says may raise stake

By Janaki Krishnan

MUMBAI, Jan 27 (Reuters) - Shares in fraud-scarred Satyam Computer Services Ltd (News) jumped more than 28 percent on Tuesday after engineer Larsen&Toubro (News) said it may raise its stake in the outsourcing firm beyond 12 percent.

'We don't rule out moving from 12 to 15 percent,' L&T Chairman A.M. Naik told an analysts call, adding it would first wait for more clarity on Satyam's financial position.

Larsen&Toubro, India's biggest engineering and construction firm, valued at around $7.7 billion, trebled its Satyam stake on Friday after speaking to some of the software services exporter's customers and on hopes the government would help rescue the firm, Naik said.

Satyam has been struggling for survival since Jan. 7 when founder Ramalinga Raju resigned as chairman revealing profits had been overstated for years and $1 billion in cash on the books did not exist.

'I have been in touch with every single leader you can think of in this whole transaction ... at the board that exists now, at the government level ... because this company is under very close monitoring by the government,' Naik said.

'We have got a good report on Satyam's services,' he added. 'We have been constantly encouraged by the government that this is the company they would like to save.'

Satyam's six-member board, appointed by the government after the country's largest corporate fraud, was meeting in the southern city of Hyderabad to discuss L&T's expanded stake, how to secure funding to pay salaries and bills, and a shortlist for the posts of chief executive and chief financial officer.

L&T had previously held a 4 percent stake in Satyam -- whose global clients include General Electric, Nestle and Caterpillar Inc -- before Raju's stunning revelations of years of accounting fraud.

Naik, who hopes to use Satyam to expand L&T's small outsourcing unit, said that by raising its holding in Satyam, L&T had cut its average acquisition cost to about 80 rupees a share from 174 rupees.

'We have taken into our calculation that there will be value erosion up to a point before stabilisation of confidence,' he said. 'Even if we don't acquire, there may be a counter bid.

'Somebody is going to jump into the fray. Once what we know becomes more clear and once others come to know, the price will move,' he added.

Second and third tier companies such as L&T Infotech have to consolidate, Naik said, adding that Infotech would grow by as much as the industry's best this year and reach $500 million in revenue.

Satyam shares, which have slumped by three-quarters since the disclosures, were up 20 percent at 46.70 rupees by 0822 GMT, while L&T lost 1.2 percent. The main stock index gained 2.9 percent. Satyam stock was dropped from the benchmark index on Jan. 12.

Raju, the company's former managing director and the chief financial officer are in police custody in Hyderabad, and police said at the weekend they arrested two partners at Satyam's auditors, PricewaterhouseCoopers.

(Writing by Narayanan Somasundaram; Editing by Ranjit Gangadharan and Ian Geoghegan) Keywords: SATYAM/

(janaki.krishnan@thomsonreuters.com, +91-22 66369138; Reuters Messaging: janaki.krishnan.reuters.com@reuters.net)

COPYRIGHT

Copyright Thomson Reuters 2009. All rights reserved.

The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.

Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission

http://ih.advfn.com/p.php?pid=nmona&cb=1233038048&article=35972975&symbol=N^CTIC

SEATTLE, Jan. 27 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today that after communication with the Food and Drug Administration (FDA), CTI expects to begin submission of a rolling New Drug Application (NDA) and request priority review for pixantrone to treat relapsed aggressive non-Hodgkin's lymphoma (NHL) in the first quarter of 2009. If granted priority review a decision on the NDA could occur before the end of 2009.

"This communication from the FDA is a significant milestone for the Company and for patients with relapsed aggressive NHL as this could be the first drug approved for this unmet medical need," noted James A. Bianco, M.D. Chief Executive Officer of CTI. "With the potential for three drug approvals in 2009 we are on track to meet our objective of cash flow break even in the fourth quarter of this year."

The EXTEND clinical trial was a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

CTI announced in November 2008 that it had achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778). Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increased the overall response rate (CR/uCR+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003). CR/uCR and ORR were determined by an independent assessment panel that was blinded to the treatment assignments.

The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004 and pixantrone has received fast track designation for this indication.

About Pixantrone

Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the results of complete safety information, the ability of the company to file a rolling NDA in the first quarter of 2009, determination by the FDA that the PIX301 trial is insufficient to support an NDA filing and that the FDA would grant priority review, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the Company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 E: http://www.celltherapeutics.com/press_room

Investors Contact: Ed Bell T: 206.272.4345 Lindsey Jesch Logan T : 206.272.4347 F : 206.272.4434 E: http://www.celltherapeutics.com/investors

DATASOURCE: Cell Therapeutics

CONTACT: media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,

, or investors, Ed Bell, +1-206-272-4345, or Lindsey Jesch

Logan, +1-206-272-4347, fax, +1-206-272-4434, , all of

Cell Therapeutics

Web site: http://www.celltherapeutics.com/

Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission

http://ih.advfn.com/p.php?pid=nmona&cb=1233038048&article=35972975&symbol=N^CTIC

SEATTLE, Jan. 27 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today that after communication with the Food and Drug Administration (FDA), CTI expects to begin submission of a rolling New Drug Application (NDA) and request priority review for pixantrone to treat relapsed aggressive non-Hodgkin's lymphoma (NHL) in the first quarter of 2009. If granted priority review a decision on the NDA could occur before the end of 2009.

"This communication from the FDA is a significant milestone for the Company and for patients with relapsed aggressive NHL as this could be the first drug approved for this unmet medical need," noted James A. Bianco, M.D. Chief Executive Officer of CTI. "With the potential for three drug approvals in 2009 we are on track to meet our objective of cash flow break even in the fourth quarter of this year."

The EXTEND clinical trial was a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

CTI announced in November 2008 that it had achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778). Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increased the overall response rate (CR/uCR+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003). CR/uCR and ORR were determined by an independent assessment panel that was blinded to the treatment assignments.

The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004 and pixantrone has received fast track designation for this indication.

About Pixantrone

Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the results of complete safety information, the ability of the company to file a rolling NDA in the first quarter of 2009, determination by the FDA that the PIX301 trial is insufficient to support an NDA filing and that the FDA would grant priority review, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the Company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 E: http://www.celltherapeutics.com/press_room

Investors Contact: Ed Bell T: 206.272.4345 Lindsey Jesch Logan T : 206.272.4347 F : 206.272.4434 E: http://www.celltherapeutics.com/investors

DATASOURCE: Cell Therapeutics

CONTACT: media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,

, or investors, Ed Bell, +1-206-272-4345, or Lindsey Jesch

Logan, +1-206-272-4347, fax, +1-206-272-4434, , all of

Cell Therapeutics

Web site: http://www.celltherapeutics.com/

Raser Technologies Inc. [RZ]

is an environmentally focused technology licensing and development company operating in two business segments. Raser’s Power Systems segment is seeking to develop clean, renewable geothermal electric power plants and bottom-cycling operations, incorporating licensed heat transfer technology and Raser’s Symetron™ technology developed internally by its Transportation and Industrial Technology segment. Raser’s Transportation and Industrial Technology segment focuses on extended-range plug-in-hybrid vehicle solutions and using Raser’s Symetron™ technology to improve the torque density and efficiency of the electric motors and drive systems used in electric and hybrid-electric vehicle powertrains and industrial applications.

*****************************************************************
...added to my LONGTIME-portfolio some "RZ"

HOMEPAGE: http://www.rasertech.com/index.html

IHUB-THREAD: http://ih.advfn.com/p.php?pid=squote&cb=1232986574&symbol=rz

STOCKCHARTS: http://stockcharts.com/h-sc/ui?s=RZ&p=D&b=5&g=0&id=0

SHORT QUOTE: http://www.shortsqueeze.com/?symbol=rz&submit=Short+Quote%99

******************************************************************

01/14/09 Raser Technologies Announces Schedule Of Remaining Commissioining Activities And Delivery Of Power To Anaheim
http://www.rasertech.com/news/scripts/full-news.php?1231941420

...beginning the week of January 25th, the Company expects the cap to be raised further and to be able to ramp delivery of power up to 5-8 MW in various stages with the final ramp up to full capacity expected in February.

Raser Technologies Inc. [RZ]

ihub-thread: http://ih.advfn.com/p.php?pid=squote&cb=1232986574&symbol=rz

Short Quote: http://www.shortsqueeze.com/?symbol=rz&submit=Short+Quote%99

Raser Technologies Inc. [RZ]

ihub-thread: http://ih.advfn.com/p.php?pid=squote&cb=1232986574&symbol=rz

Short Quote: http://www.shortsqueeze.com/?symbol=rz&submit=Short+Quote%99

... now it takes more time to recover!

LINK

http://www.etfinnovators.com/search?q=fda+calendar

FDA Decision Calendar - Update 01/24/09

http://4.bp.blogspot.com/_Du0YWLylHeA/SXr4axkky6I/AAAAAAAAAx8/mWxE4gx2iW8/s1600-h/fdac24jan09.JPG